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Deep Brain Stimulation: A Paradigm
Shifting Approach to Treat
Parkinson’s Disease
Patrick Hickey* and Mark Stacy
Department of Neurology, Duke University Medical Center, Durham, NC, USA
Parkinson disease (PD) is a chronic and progressive movement disorder classically
characterized by slowed voluntary movements, resting tremor, muscle rigidity, and
impaired gait and balance. Medical treatment is highly successful early on, though the
majority of people experience significant complications in later stages. In advanced PD,
when medications no longer adequately control motor symptoms, deep brain stimulation
(DBS) offers a powerful therapeutic alternative. DBS involves the surgical implantation
of one or more electrodes into specific areas of the brain, which modulate or disrupt
abnormal patterns of neural signaling within the targeted region. Outcomes are often
dramatic following DBS, with improvements in motor function and reductions motor
complications having been repeatedly demonstrated. Given such robust responses,
emerging indications for DBS are being investigated. In parallel with expansions of
therapeutic scope, advancements within the areas of neurosurgical technique and
the precision of stimulation delivery have recently broadened as well. This review
focuses on the revolutionary addition of DBS to the therapeutic armamentarium for
PD, and summarizes the technological advancements in the areas of neuroimaging
and biomedical engineering intended to improve targeting, programming, and overall
management.
Keywords: Parkinson’s disease, deep brain stimulation, subthalamic nucleus, globus pallidus, pedunculopontine
nucleus
INTRODUCTION
Parkinson disease (PD) is a chronic neurodegenerative disorder classically characterized by
motor manifestations including slowed voluntary movements, resting tremor, muscle rigidity, and
impaired gait and balance (Stacy, 2009). With a prevalence of 0.3% that increases with advancing
age (Fahn, 2003), PD is projected to have a significant worldwide economic impact in the coming
years (Dorsey et al., 2007; Kowal et al., 2013). Although the pathogenesis of PD has not been
fully elucidated, motor deficits are associated with selective loss of pigmented neurons, which
originate in the substantia nigra pars compacta and terminate in the striatum (Jellinger, 2007).
Medical therapies are largely aimed at increasing the availability of striatal dopamine and typically
result in a brisk symptomatic improvement in most PD patients. Unfortunately, this response
becomes less reliable and less predictable over time, and after 5 years of therapy, medication-
related complications develop in a majority of patients. Motor complications, such as dyskinesia,
wearing-off, and “on–off” fluctuations, characterized by a sudden, sometimes unpredictable loss
of treatment effect are well-recognized (Nutt, 2001; Stacy, 2009). Non-motor complications are
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also prevalent and include impulse control disorders, such
as pathological gambling, compulsive spending, binge eating,
hyperlibidinous behaviors, and compulsive motor activity
(Weintraub et al., 2015).
In advanced stages of PD, when medications no longer
adequately control motor symptoms, deep brain stimulation
(DBS) offers a powerful therapeutic alternative. DBS is a surgical
therapy involving the implantation of one or more electrodes
into specific regions of the brain, which deliver electrical
stimuli to modulate or disrupt abnormal patterns of neural
signaling within the targeted region. The results are often
dramatic, with improvements in motor function and motor
complications having been repeatedly demonstrated. Given such
robust responses, emerging indications for DBS are being
investigated. In parallel with expansions of therapeutic scope,
advancements within the areas of neurosurgical technique and
the precision of stimulation delivery have recently broadened
as well. This review summarizes the revolutionary addition of
DBS to the therapeutic armamentarium for PD as well as recent
advances in treatment delivery.
HISTORICAL PERSPECTIVE OF DEEP
BRAIN STIMULATION
Prior to the discovery of levodopa, surgical interventions
were the most efficacious treatment for PD symptoms, but
primarily focused on the reduction of bothersome tremor.
Early approaches targeted the pyramidal tracts, with lesioning
either at the point of origin in the cortex or the descending
pathways through the brainstem and cervical spinal cord
(Cooper, 1956). Although tremor was reliably improved
following surgery, hemiparesis was an inevitable consequence.
However, in 1952, Dr. Irving Cooper inadvertently interrupted
the anterior choroidal artery while performing a mesencephalic
pedunculotomy in a patient with PD. Ligation of the vessel was
required, though what resulted was a serendipitous reduction
in rigidity and tremor with preservation of motor and sensory
function. Cooper reasoned the favorable outcomes were due to
infarction of the medial globus pallidus. An expansion of ablative
stereotactic surgery followed, aided by the earlier development
of the stereotactic frame and methods of targeting deep brain
structures, including the basal ganglia and thalamus. However,
the success of these approaches was limited, partly because
of inaccurate, imprecise, and inconsistent targeting. Moreover,
intentionally created bilateral brain lesions frequently led to
irreversible deficits in speech, swallowing, and cognition.
Surgical intervention for PD faded in popularity in the early
1970s after the arrival of levodopa, which radically transformed
the pharmacological treatment of PD. Levodopa was soon
accepted as the preferred treatment for PD while demonstrating
a positive impact on disability, quality of life, and longevity.
However, it also became clear that patients on levodopa and other
antiparkinsonian drugs often develop significant drug-induced
complications, such as involuntary movements (dyskinesias),
motor fluctuations (wearing-off, and “on–off” fluctuations),
hallucinations, and psychosis. Such complications, combined
with a growing understanding of basal ganglia and cerebellar
circuitry, rekindled interest in earlier surgical procedures.
In 1987, Dr. Alim-Louis Benabid explored high frequency
stimulation of the thalamus while operating on an elderly
man who had previously undergone contralateral ablation for
tremor. Given his concerns for creating bilateral lesions, Benabid
implanted a wire into the untreated thalamus with four metal
contacts at its tip, which was then connected to an external
battery source. By passing high-frequency electrical stimulation
through the wire, Benabid and colleagues demonstrated that
chronic electrical stimulation of the subcortical brain (DBS) was
as effective as thalamotomy for tremor suppression (Benabid
et al., 1994). Soon thereafter, the use of DBS at other basal ganglia
locations was explored for refractory movement disorders,
including PD.
CLINICAL EXPERIENCE WITH DEEP
BRAIN STIMULATION
The advent of modern DBS led to a major change in the
therapeutic armamentarium for movement disorders. DBS
rapidly overtook lesioning as the surgical treatment of choice for
refractory movement disorders due to a number advantages: it
is nondestructive and several stimulation parameters, including
the location, size, intensity, and the shape of the stimulating
current field can be adjusted following surgical implantation.
These properties allow clinicians to program the DBS device in
such a way as to maximize motor benefits while minimizing side
effects, most of which are caused by the inadvertent stimulation
of structures adjacent to the intended target. Perhaps most
importantly for patients with PD, DBS has a lower reported
complication rate when used bilaterally (Tasker, 1998).
Since the first application of DBS for PD in 1993,
several thousand patients worldwide have undergone surgical
implantation. While many studies have reported the benefits and
durability of this therapy (Krack et al., 2003; Fasano et al., 2010;
Moro et al., 2010), six large-scale, randomized, controlled clinical
trials have been performed (Deuschl et al., 2006; Okun et al., 2009,
2012; Weaver et al., 2009; Williams et al., 2010; Schuepbach et al.,
2013). Given the pervasive nature of this disease, the end points of
these trials have appropriately included quality of life measures,
the severity of motor symptoms in the medication “off” state,
and time spent in the “on” state without troublesome motor
symptoms (e.g., dyskinesia, as assessed by means of a dyskinesia
diary).
The first of these trials was conducted in Germany and Austria
and included 156 PD patients with advanced disease and severe
motor symptoms (Deuschl et al., 2006). Subjects were randomly
assigned to undergo bilateral DBS of the subthalamic nucleus
(STN) or to receive optimized and individualized drug therapy
according to best practice guidelines. At 6 months, patients
assigned to receive DBS had significantly better quality of life
measures (mean PDQ-39 31.8 vs. 40.2) and motor scores (mean
UPDRS-III 28.3 vs. 46.0). In addition, dyskinesia in the “off” state
reduced by 54% in the DBS group but remained unchanged in the
medication group.
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Four subsequent trials demonstrated similar efficacy of DBS
in advanced PD patients (Okun et al., 2009, 2012; Weaver
et al., 2009; Williams et al., 2010). Taken together, the most
important benefit of neurostimulation is the improvement of
motor function during the “off” state, in particular reducing the
duration and severity of motor symptoms when medications are
least effective. Thus, DBS patients are likely to experience an
improvement in mobility during times when it would otherwise
be at its poorest, thereby allowing a more reliable and higher
level of overall function. Furthermore, neurostimulation results
in a reduction in the subjectively measured “off” time and in the
severity of dyskinesias during the “on” state (Figure 1).
At present, DBS is typically considered in advanced PD and
thus limited to patients for whom medications are no longer
FIGURE 1 | Mobility and motor function pre- and post-deep brain
stimulation. In advanced Parkinson’s disease (A) the duration of response
after a single dose of levodopa becomes progressively shorter, thus it
becomes increasingly difficult to maintain a satisfactory ON state, with OFF
periods (purple bar) and dyskinesia often predominating. While most patients
continue to take medication after surgery, the goal following DBS (B) is a
reduction in the duration and severity of OFF time, more consistent and longer
ON time, as well as an improvement in dyskinesia. Advances in sensing and
stimulating technologies promise to enhance DBS delivery, further reducing
variability in motor function and improving clinical efficacy. Adapted from
Deuschl and Agid (2013).
providing adequate relief of symptoms. As a result, patients who
undergo DBS are a mean of 58.6 years old with mean disease
duration of 12 years (Deuschl et al., 2006; Okun et al., 2009,
2012; Weaver et al., 2009; Williams et al., 2010). In targeting
this select patient population, neurostimulation is used in fewer
than 2% of all patients with PD. A more widespread and
inclusive application of surgery may be restrained by a number
of factors, including a lack of familiarity with the procedure, the
presence of conditions or comorbidities that may make patients
ineligible for the surgery, or concerns for potential surgical
risks (especially in elderly individuals) (Deuschl et al., 2013a).
The effect that advancing age has on DBS candidacy, surgical
complications, and outcomes is of increasing importance as the
number of individuals with PD is expected to rise in the coming
years (Dorsey et al., 2007). Encouragingly, there is accumulating
evidence supporting the safety and efficacy of DBS in elderly PD
patients (DeLong et al., 2014; Levi et al., 2015; Mitchell et al.,
2015). Together, these reports suggest that age alone should not
be a primary exclusion factor for determining surgical candidacy.
Instead, all patients should be viewed on the basis of their medical
issues, their disease symptoms (i.e., tremor, dyskinesias, gait and
postural instability, etc), and whether there is sufficient lifespan
to offer a long-term benefit.
While DBS appears to be a practical option in aged individuals,
the progressive nature of PD suggests that advanced age will be
associated with accumulating impairments in quality of life and
limitations of psychosocial function. Given the robust response
to neurostimulation in later stages of PD, consideration has
been given to whether DBS should be considered earlier in the
disease course, perhaps preventing the development of motor
complications at a much earlier time point and reducing the
burden of such long-term sequelae. To help address this concern,
the recently reported EARLYSTIM trial evaluated the benefit of
STN DBS compared with medical treatment in 251 PD patients
with a mean of 7.5 years of disease duration and at a mean age of
52.5 years (Schuepbach et al., 2013). Subjects were followed for
up to 2 years in this multicenter prospective study. Compared
with the medical treatment group, outcomes including quality
of life and motor disability favored stimulation in these patients
just beginning to experience complications of medical therapy.
This important investigation provided compelling evidence
supporting STN neurostimulation at an earlier disease time
point than traditionally considered with regard to cogent motor
and non-motor outcome parameters. However, some caution
may be advised in extending the promising results to routine
clinical practice as patients met strict inclusion criteria with the
absence of contraindications, and the study was completed at
highly experienced implantation centers under the supervision
of multidisciplinary surgical teams (Deuschl and Agid, 2013).
It has been further suggested that DBS at the earliest stage
of motor PD may slow the progression of the disease, actually
preventing the development of late-stage complications and
providing a better overall quality of life (Charles et al., 2008;
Hacker et al., 2015). A recent pilot study in PD patients being
treated medically for 6 months to 4 years at enrollment, and
without motor complications, demonstrated the feasibility of
enrolling subjects with early stage PD (Charles et al., 2014;
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Hacker et al., 2015). After two years of follow up, the surgical
group experienced a reduction in the relative risk of symptom
worsening (which was defined as both a ≥3 point increase in
UPDRS Part III and a ≥1 point increase in UPDRS Part IV)
and required less PD medications. Additional long-term analysis
will provide further insight into potential benefits of DBS in
this cohort, though as with any invasive therapy, safety will also
be an important determinant of widespread application in this
population (Hariz, 2015).
It is clear that DBS has revolutionized the treatment of
advanced PD, providing improvements in quality of life and
motor function, while allowing for reductions in drug-related
dyskinesia. Extending beyond these measures, evidence suggests
that neuromodulationmay even reducemortality and admissions
to a residential care home (Ngoga et al., 2014). In addition, recent
investigations have further established the safety and efficacy
of this therapy at both ends of the disease spectrum, possibly
expanding the utilization of this powerful therapy.
INDIVIDUALIZED STIMULATION DELIVERY
The two most widely utilized and investigated brain targets for
PD are the STN and the internal segment of the globus pallidus
(GPi; Figure 2). Both have been studied extensively and provide
fairly equivalent improvements in the cardinal motor symptoms
of PD, dyskinesia, and quality of life. However, some notable
differences between these two targets may influence surgical
decisions for an individual patient. For example, the Veterans
Affairs Cooperative Study showed that STN stimulation had
a higher rate of potential worsening of cognition and mood,
but allowed more aggressive medication reduction after surgery
(Follett et al., 2010). Further, GPi stimulation has been associated
with better control of axial motor symptoms including speech
and swallowing function (St George et al., 2010; Odekerken
et al., 2013; Troche et al., 2014). These distinctions highlight
the importance of a comprehensive patient evaluation by a
multidisciplinary team in order to maximize potential surgical
outcomes.
Unfortunately, interventions at these conventional targets are
generally not effective against levodopa-unresponsive symptoms
such as gait and balance disturbances and freezing of gait, which
are important determinants of quality of life and significantly
impact activities of daily living (Table 1). This may be explained
by the degeneration of several non-dopaminergic neuronal
structures and feedback loops, which likely also contribute to
certain PDmotor features and appear crucial in the development
of gait and balance disorders (Grabli et al., 2013). Thus, novel
stimulation techniques, brain targets, and technologies have been
investigated in an attempt to expand the utility of DBS and
treat symptoms that are less responsive following standard DBS
implantation.
Novel Brain Targets
To help address resistant axial and gait symptoms associated
with PD, there has been persistent interest in pedunculopontine
nucleus (PPN), a cholinergic nucleus located within the
mesencephalic locomotor region (MLR), functionally defined as
TABLE 1 | The Effect of Levodopa and DBS in Advanced PD.
Symptom Effect of levodopa Effect of DBS
Rigidity Improves Improves
Bradykinesia Improves Improves
Tremor Improves Improves
Gait/Balance Individual components of
gait and balance appear to
respond uniquely
Evidence supports better results
with GPi DBS
Dyskinesia May worsen Improves
Off time Medicine adjustments may
not improve off time in
advanced PD
Improves
Cognitive
Function
May worsen during off
times
Studies have demonstrated
worsened verbal fluency and set
shifting abilities during complex
tasks following STN DBS
Mood
and
apathy
May improve May worsen with STN DBS,
especially with rapid medication
reduction and in patients with
history of ICD
Speech No change May worsen, especially with
bilateral STN DBS
Quality of
life
Improves Improves
Key: PD, Parkinson’s disease; DBS, deep brain stimulation; STN, subthalamic nucleus;
GPi, internal segment of the globus pallidus; ICD, impulse control disorders.
the area of the brainstem responsible for locomotion (Figure 2).
Initial clinical investigations of PPN stimulation demonstrated
improvement in axial and postural symptoms in PD patients with
gait disturbances, although subsequent studies have tempered
enthusiasm for this intervention with outcomes being highly
variable (Mazzone et al., 2005; Plaha and Gill, 2005; Stefani
et al., 2007; Ferraye et al., 2011; Thevathasan et al., 2012).
Several critical issues have likely contributed to this variability,
including disagreements over proper anatomic lead placement,
whether PPN was utilized as a standalone target or combined
with stimulation of other brain sites (e.g., along with STN
stimulation), and unilateral vs. bilateral implantation.
Other locations of interest include the centromedian
thalamus, zona incerta, and the substantia nigra (SNr). The SNr
is also part of the MLR, with dense reciprocal interconnections
to the PPN and brainstem circuitries. Early investigations have
shown promise, demonstrating improvement in gait freezing
with combined SNr/STN-DBS (Weiss et al., 2011, 2013) and gait
and posture with SNr-DBS alone (Chastan et al., 2009). Larger
and more rigorous studies are needed to determine the viability
of these unique stimulation targets for refractory axial symptoms
in PD. Clearly these are desired investigations as expansion of
DBS to further address medically refractory symptoms of PD
could once again revolutionize management of this disease.
Novel Lead Design
Since, the advent of therapeutic DBS more than 25 years ago,
there has been little change to the classic DBS electrode, which
consists of a flexible 1.27-mm- diameter cylinder with a stack
of four platinum/iridium cylindrical contacts, 1mm in height,
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spaced either 1 or 0.5mm apart at the distal end (Medtronic
Inc, Minneapolis, MN). The electrode is implanted into a brain
target and attached to an implanted pulse generator (IPG),
which provides stimulation as a continuous spherical electric
field around the active contact(s). The electrical parameters for
chronic stimulation are selected during DBS programming, the
goal of which is to screen for the optimal electrode polarity,
amplitude, pulse width, and frequency which avoids adverse
effects of stimulation, while optimizing benefits and minimizing
current consumption. At present, this is most commonly
achieved by choosing either monopolar or bipolar stimulation
and varying combinations of active contacts, thus adjusting
current flow through the desired target area (Volkmann et al.,
2006). In monopolar stimulation, the active contact is set as the
negative pole, or cathode, and the internal pulse generator case
is set as the positive pole, or anode. This creates a wide electric
field with relatively equal spread of stimulation in all directions.
In bipolar stimulation, another electrode contact serves as
the anode, minimizing the spread of current and yielding a
narrower area of stimulation (Butson and McIntyre, 2008)
(Figure 3).
The optimal functional area within DBS target structures is
limited in size and in close proximity to surrounding structures,
thus classical monopolar or bipolar stimulation sometimes fails
to provide sufficient beneficial effects or causes undesired side
effects at stimulation amplitudes needed to sufficiently control
symptoms. The emergence of stimulation-related adverse effects
is an important limitation of DBS therapies, occurring regularly
in up to 13% of patients (Timmerman et al., 2015). In fact,
the current state-of-the-art lead design is particularly sensitive
to surgical targeting errors that are tangential to the lead’s
primary axis and studies have demonstrated that targeting errors
of only 2mm can result in unwanted side effects that negate
the intended therapeutic response (Montgomery, 2012). When
conventional programming techniques fail to achieve desired
results, interleaving stimulation (Medtronic Inc., Minneapolis,
MN) may provide an alternative option. Interleaving is a novel
and readily available feature that allows independent stimulation
of two contacts of the quadripolar DBS electrode, which rapidly
alternate from pulse to pulse between each other. Different
values for voltage and pulse width may be used between the
active contacts, which allow the clinician to shape the field of
FIGURE 2 | Electrode Location for Deep Brain Stimulation. Approved locations for implantation of deep brain stimulation (DBS) include both the subthalamic
nucleus and the internal segment of the globus pallidus. The pedunculopontine nucleus has showed promise as a potential DBS target, especially in regards to axial
symptoms such as gait and balance dysfunction. During implantation, a burr hole is made in the skull through which the electrode is passed down to the target. An
extension is tunneled under the skin of the scalp and connected to an impulse generator located in the chest below the clavicle.
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FIGURE 3 | Deep brain stimulation electrode configurations. (A)
Conventional quadripolar electrode producing a spherical electrical field that
may spread outside the target area, causing side effects. (B) Multipolar 32
contact electrode that allows directional steering of the field, reducing the
potential for stimulation side effects. (C) Eight contact electrode with multiple
independent current control (MICC), enabling the allocation of completely
different stimulation parameters independently to each electrode contact.
electrical stimulation along the vertical axis of the electrode.
Initial investigations of this technology suggest that it may have
limited utility in specific situations (Miocinovic et al., 2014).
To further address the limitations of available stimulation
technology, segmented electrodes have been designed that allow
better contouring of the electrical field, thus activating targeted
neural pathways while reducing the risk of unwanted side effects.
One such novel electrode design (Boston Scientific Corporation,
Marlborough, MA) is capable of delivering multiple source
constant current, enabling the allocation of completely different
stimulation parameters independently to each of eight contacts
of the electrode (Figure 3). A recently reported prospective,
multicenter, non-randomized, open-label trial of bilateral STN
DBS in 40 PD patients utilizing this technology demonstrated
excellent motor benefit with improved quality of life measures
(Timmerman et al., 2015). While this allows more tailored
stimulation within the brain target, the current delivered will
still encompass the tissue around the whole circumference of the
active contact, limiting electrical field shaping to the vertical axis
of the electrode.
Given the close proximity of subcortical DBS targets to
surrounding neuronal structures and white matter pathways,
there remains a need for true current steering and true
electric field shaping around all three directional axes. Two
approaches have been investigated to address this need, including
a novel electrode with 32 contacts distributed evenly around
the circumference of the lead (Figure 3), which enables current
steering in four different directions (Contarino et al., 2014)
and a lead with four rings, where each ring consists of three
independent electrodes with three different orientations allowing
independent stimulation in any of the three directions (Pollo
et al., 2014). Investigations of both electrode designs have
shown the ability to reproduce benefits equivalent to standard
electrodes, while significantly widening the therapeutic window
and positively influencing the thresholds for programming
(Contarino et al., 2014; Pollo et al., 2014). Chronic implantation
is now needed to establish the usefulness of directional steering
in the long-term.
Further, advancements in DBS lead design continue with the
goal of enhancing the spatial precision of stimulation (Connolly
et al., 2016). With such progress, the possibility exists to
target symptoms traditionally refractory to currently available
neurostimulation algorithms, and to design new treatments,
targeting small brain areas currently inaccessible because of
commonly induced side effects. The indications for DBS continue
to expand, and future targets for DBS could include small
subnuclei in the hypothalamus, in the fornix, the upper
brainstem, or even the medulla oblongata and spinal cord.
Adaptable DBS
The therapeutic success of DBS depends not only on accurate
surgical targeting and electrode implantation, but also on
the ability to optimize stimulation parameters. Presently,
DBS programming in the clinic is an iterative process in
which stimulation settings are adjusted in order to maximize
therapeutic benefits while minimizing side effects. Although
many surgical patients require minimal stimulation adjustment
following implantation, a significant number require several
months of regular parameter modification before optimal
therapeutic results are achieved (Okun et al., 2005; Kluger
et al., 2011). A number of inherent limitations of DBS may
contribute in these situations. While PD is a dynamic and
progressive disease, DBS is classically delivered in an open-
loop fashion, in other words, the neurostimulator is blind
to the neural activity it is modulating and does not adjust
its parameters based on any neural or kinematic feedback.
This open-loop configuration means that any adjustment is
dependent on the subjective experiences of both the patient and
clinician; there is no objective feedback to support parameter
optimization. In addition, the therapeutic response observed
upon adjustment does not guarantee sustained therapeutic
effects; disease progression, cognitive and motor load, mood,
and concurrent drug therapy can all impact the effectiveness
of stimulation, necessitating additional programming sessions
(Obeso and Guridi, 2001; Kupsch et al., 2011). Further, DBS
adjustment sessions are inefficient and time consuming, allowing
only a limited exploration of settings during each procedure.
Finally, programming can vary greatly depending on target
location and the symptoms being treated for any given disorder
(e.g., tremor may require different settings than gait).
To overcome these limitations and improve DBS delivery, the
establishment of a “closed loop” system would allow therapy
adjustment in real-time according to quantifiable and objective
brain and behavioral changes while reducing the frequency
of clinical interventions. A responsive DBS system capable
of sensing local neuronal activity and automatically adjusting
stimulation parameters in response to changes within the brain
may improve clinical efficacy, decrease stimulation-induced side
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effects, and prolong battery life. Recent proof-of-principle studies
have shown that by personalizing and optimizing stimulation
parameters in real time, the efficacy and efficiency of DBS as an
adaptable program can be potentially improved (Bronte-Stewart
et al., 2009; Grahn et al., 2014). While individualized stimulation
could revolutionize DBS delivery, a significant challenge is to
determine a reliable and robust feedback signal in a chronically
behaving human. Various responses have been considered and
evaluated such as movement kinematics (Mera et al., 2011)
or neurotransmitter fluctuations in a target nucleus (Grahn
et al., 2014). However, perhaps the most thoroughly investigated
biophysiological signal for an adaptive DBS system is the
measurement of local neural activity.
The striatal dopamine depletion associated with PD produces
strong neural synchronization, bursting and sustained low
frequency oscillations within the basal ganglia motor circuit.
In the unmedicated PD patient, local field potentials (LFPs)
recorded from the STN show an exaggerated oscillatory activity
in the beta range (13–30Hz) while at rest. Resting state beta
band power has the potential to be a useful metric to guide an
adaptive DBS system, and has a number of potential advantages.
Parkinsonian motor symptoms, including bradykinesia and
rigidity, are related to strong and sustained activity in beta-
frequencies (Kühn et al., 2006; Hammond et al., 2007; Little
et al., 2012) while dopaminergic medication and high-frequency
DBS attenuates abnormal beta activity (Brown, 2003; Bronte-
Stewart et al., 2009; Whitmer et al., 2012). In addition, local field
potentials can be directly recorded from the stimulating electrode
allowing real time feedback and modulation. Early investigations
utilizing beta band activity as a neural marker for an adaptive
DBS system and have shown promise in improving stimulation
efficiency (Little et al., 2013; Quinn et al., 2015). While clinical
applications may be affected by variations between different PD
phenotypes and susceptibility to artifact, further investigations
into beta band as a reliable biophysiological signal for an adaptive
DBS system are warranted and ongoing.
ADVANCES IN IMAGING FOR DEEP BRAIN
STIMULATION
Along with new developments in the DBS technology itself,
advances in imaging techniques and in related visualization
software programs will provide a major impact on the field of
invasive neurostimulation.
Image Guided DBS
The traditional method of DBS implantation employs detailed
brain imaging to first delineate the intended target. This is
typically achieved by use of stereotactic magnetic resonance
imaging (MRI), which enables direct visualization of brain
anatomy and the intended targets utilized for PD. Stereotaxy
determines accurate localization of intracranial targets by
ascertaining triplanar coordinates with reference to a fixed
point, thus providing access to surgical targets deep within
the brain in a minimally invasive fashion. The target is then
constructed by use of graphic tools embedded within available
stereotactic navigation software and registered in a stereotactic
coordinate system. This planning stage allows pre-operative
target adjustments based on individual patient anatomy and the
selection of a skull entry point that avoids interrupting vessels of
the cortical surface and sulci, ventricles, or other eloquent brain
structures.
Functional neurosurgery involves the precise surgical
targeting of anatomic structures to modulate neurologic
function, such as abnormal movements. As such, accuracy and
precision of electrode placement is of great importance. Most
surgical teams utilize some form of electrophysiological mapping
or stimulation testing to ensure that the optimal location within
the target has been implanted. This exploration may consist of
microelectrode recording of single neurons, local field potential
recording of populations of neurons, or macrostimulation
of the intended target with direct observation of the patient
for improvement in symptoms and/or stimulation-induced
side effects. Microelectrode recording provides adjustment for
interpatient variability in physiology and symptomatology, and
recording during passive movement of a limb can confirm an
association with motor function and help ensure implantation
within the motor subterritories of the intended brain target.
However, these techniques require that the patient be awake for
much of the procedure, which is difficult for some to tolerate. In
addition it is time consuming, technically demanding, and often
necessitates multiple brain penetrations.
Electrophysiological mapping helps ensure proper anatomic
position of the DBS electrode in the brain, which is essential
for safety, selection of stimulation parameters, and the ultimate
success of the therapy. Various types of imaging modalities may
also aid surgical targeting and both computed tomography (CT)
andMRI have been successfully integrated into the intraoperative
workflow of DBS surgery. One approach involves imaging the
implanted microelectrode with registration back to the pre-
operative planned trajectory. The physiologic data are then
interpreted in light of the position of the electrodes on the
scan. A subsequent track can be created, or the DBS lead can
replace one of the microelectrodes. Imaging of the DBS lead
after placement assures the surgeon that its position is acceptable.
Evidence supports that this approach allows for correction of the
average 2-mm targeting error seen with traditional stereotactic
approaches (Starr et al., 1999; Kelman et al., 2010; Shahlaie et al.,
2011; Holloway and Docef, 2013).
For nuclei targeted for PD, such as the GPi and STN,
which are visible on particular MRI sequences, new techniques
have been developed for implanting DBS leads using real-
time interventional MRI (iMRI) guidance without the use of
microelectrode recordings or intraoperative test stimulation
(Martin et al., 2009; Starr et al., 2009, 2010). By utilizing a skull-
mounted aiming device (SmartFrame; MRI Interventions, Irvine,
CA) in collaboration with a software platform (ClearPoint;
MRI Interventions), this system can stream MR images in real
time from any 1.5-T or 3-T scanner, and guide the surgical
team through the implantation procedure. DBS implantation is
performed entirely within the MRI scanner, and relies on direct
visualization of the STN or GPi as the sole method of targeting.
A stereotactic frame is not needed, MRI is the only imaging
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modality used, so no image fusion is needed and targeting is
performed after cranial opening so brain shift can be taken into
account.
This method marks a departure from traditional stereotactic
techniques by eliminating the need for preoperative MR images,
which cannot account for intraoperative brain shift due to
pneumocephalus or CSF loss. Real time imaging enhances
the detection of intraoperative complications and reduces the
procedure to a single brain penetration in most cases (Starr
et al., 2010; Larson et al., 2012). This technique may also
be faster with a higher accuracy than a stereotactic frame
surgery, while producing clinical outcomes that are comparable
to traditional, awake procedures (Ostrem et al., 2013, 2016).
Using the ClearPoint system, clinically acceptable placement
can be obtained with a single brain penetration in 98% of
cases, with an average application accuracy of 0.6 to 0.8mm
from the intended target (Ostrem et al., 2013, 2016). Finally,
surgery can be performed under general anesthesia, and does not
require withholding of parkinsonian medications, thus broaden
the accessibility to those who might not otherwise be able to
tolerate awake surgery.
Advanced Imaging Techniques
The basal ganglia are components of segregated, largely closed,
reentrant loop circuits that originate in the cerebral cortex,
traverse the basal ganglia and thalamus, and return to their
individual sites of origin (Wichmann and Delong, 2006). PD
results from dysfunction of multiple motor and nonmotor
neural circuits. Although the clinical efficacy of DBS for the
cardinal features of PD has been demonstrated, the exact
mechanisms by which it induces these effects are still not
well understood. Since DBS motor outcomes are similar to
basal ganglia structural lesioning procedures, it was originally
proposed that high frequency electrical stimulation induced
inhibition by depolarization blockade of abnormal neuronal
firing within the dysfunctional motor circuit (Beurrier et al.,
2001). However, DBS mechanisms appear to be quite complex,
activating axons while simultaneously inhibiting soma (Grill and
Mclntyre, 2001; Vitek, 2002; McIntyre et al., 2004; McIntyre
and Hahn, 2010). While the net benefit of neurostimulation
would be the sum of its effects on local and remote structures,
recent research has posited that DBS relieves symptoms by the
selective stimulation of white-matter tracts (Henderson, 2012) or
by the normalization of pathologic global functional networks
(Kringelbach et al., 2011).
While much of the current understanding of basal ganglia
structure and function originated from animal studies or human
lesion or post mortem studies, white matter pathways have
recently been imaged in vivo in humans using diffusor tensor
imaging (DTI). Such advanced neuroimaging techniques have
helped validate many components of these circuits, while
also refining some overlap between pathways and enhancing
information about smaller subregions (Weingarten et al., 2015).
Beyond improving the understanding of network structure, DTI
and fiber tracking have been used to visualize white matter tracts
as a target area. Enhanced visualization of deep brain white
matter tracts raises the possibility of improved anatomically
guided DBS, which would obviate the need for patients to be
awake, could expedite the placement of the DBS leads, reduce
the need for repositioning, decrease operating time, and improve
overall patient experience and outcome. Further, detailed circuit
mapping could allow targeting of traditionally refractory PD
symptoms (e.g., gait freezing) or avoidance of common side
effects (e.g., speech changes).
Accurate electrode placement is paramount for maximizing
therapeutic benefits while minimizing potential side effects
and this begins with visualization of the DBS target during
surgical planning. As DBS acts predominantly on axons and
dendrites nearest the electrode, neuroimaging techniques that
improve approximation to intended and pathogenic targets may
dramatically improve current surgical outcomes and overcome
limitations. High-quality, distortion-free images are essential for
this endeavor. Despite advances in MRI technology, challenges
still remain with currently utilized 1.5- and 3-T T2 MRI
sequences, including geometrical distortion and poor image
quality. Newer MRI sequences, including susceptibility-weighted
imaging (SWI) and T2-weighted magnitude imaging (T2*WI),
as well as image reconstruction methods such as susceptibility-
weighted phase imaging (SWPI) and quantitative susceptibility
mapping (QSM), have shown promise in improving target
contrast and better defining target borders (Chandran et al., 2015;
He et al., 2015).
Functional connectivity studies utilizing fMRI and
multimodel analysis have demonstrated widespread changes
in PD patients, including alterations to motor networks
(Weingarten et al., 2015). Further, evidence supports an overlap
between deficits in anatomical and functional connectivity within
the sensorimotor circuit in PD, indicating a possible link between
brain structure and function (Sharman et al., 2013). As DBS has
been shown to modulate all the major components of the motor
circuit (Kahan et al., 2014), utilization of network analyses in
DBS planning and programming may allow individual tailoring
of therapy based on unique features of the abnormal network.
Future advances and refinements in neuroimaging are likely
to add to the complex neurodegenerative picture of PD that
has already developed. However, with more individualized
neuroimaging comes the potential for personalized approaches
for surgical treatment such as tailored DBS based on symptoms,
potential for progression, and co-morbidities.
In all, the DBS procedure continues to be refined, with the
goal of reducing errors and side effects, while improving patient
comfort and optimizing successful outcomes.
CONCLUSIONS AND FUTURE
DIRECTIONS
DBS was pioneered nearly three decades ago and its benefits
have been repeatedly demonstrated in patients with medically
intractable PD. Such robust outcomes have lead great interest
in the use of DBS in the treatment of other neurological
conditions such as chronic pain and medically refractory
psychiatric/behavioral conditions such as obsessive-compulsive
disorder or depression. In fact, the neurostimulation has been
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explored in more than 40 brain sites for 30 clinical disorders
(Hariz et al., 2013). In addition to its therapeutic benefits, DBS
proved to be a highly valuable tool for research, providing
a minimally invasive probe for stimulation and recording of
electrical signals from the implanted targets. This research
has provided new insights into brain network function and
dysfunction in neurologic and psychiatric disorders.
To accommodate the rapid expansion in scope, novel
technologies are under development to provide clinicians
with new tools making targeting, programming and overall
management easier. These technologies vary in focus though
converge toward providing safer and more accurate placement of
electrodes with a subsequent optimization of therapeutic benefit.
Careful evaluation of emerging technology will be imperative
to demonstrate any usefulness and/or advantage over what is
available today.
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